Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

Annals of Oncology

Volumn 8, Issue 12, 1997, Pages 1221-1228

  Vanhoefer, U ^a   Cao, S ^b   Harstrick, A ^a   Seeber, S ^a   Rustum, Y M ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Docetaxel; MRP; Multidrug resistance; Nude mice; Paclitaxel

Indexed keywords

DOCETAXEL; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PYRIDINE DERIVATIVE; RHODAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PACLITAXEL; SARCOMA, EXPERIMENTAL; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0031447927     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008290406221     Document Type: Article

References (57)

1. Spencer CM, Faulds D. Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794-847.
2. Cortes E, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55.
3. Horwitz SB, Lothstein L, Manfredi JJ et al. Paclitaxel: Mechanisms, actions and resistance. Ann NY Acad Sci USA 1986; 466: 733-44.
4. Bissery MC, Nohynek G, Sanderink GJ et al. Docetaxel (Taxotere®): A review of preclinical and clinical experience. Part 1: preclinical experience. Anti-Cancer Drugs 1995; 6: 339-55.
5. Guéritte-Voegelein F, Guénard D, Lavelle F et al. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-8.
6. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): A semi-synthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 228-91.
7. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-55.
8. Bissery MC, Guénard D. Guéritte-Voegelein F et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51: 4845-52.
9. Cabrai F, Wible L, Brenner S et al. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983; 97: 30-9.
10. Jaffrèzou JP, Dumontet C, Derry WB et al. Novel mechanism of resistance to paclitaxel (Taxol®) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 1995; 7: 517-27.
11. Roy SN, Horwitz SB. A phosphoglycoprotein associated with paclitaxel resistance in J744.2 cells. Cancer Res 1985; 45: 3856-63.
12. Gupta RS. Taxol resistant mutants of chinese hamster ovary cells: Genetic, biochemical, and cross-resistance studies. J Cell Physiol 1983; 114: 137-44.
13. Riou JF, Petitgenet O, Aynie I et al. Establishment and characterization of docetaxel (taxotere®) resistant human breast carcinoma (Calc18/TXT) and murine leukemic (P388/TXT) cell lines. Proc Am Assoc Cancer Res 1994; 35: 339.
14. Riou JF, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Comm 1992; 187: 164-70.
15. Hill BT, Whelan RDH, Shellard SA et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and drug resistant sublines in vitro. Invest New Drugs 1994; 12: 169-82.
16. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science 1992; 258:1650-4.
17. Zaman GJR, Flens, MJ, van Leusden MR et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug efflux pump. Proc Natl Acad Sci USA 1994; 91: 8822-6.
18. Slovak ML, Ho JP, Bhardwaj G et al. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 1993; 53: 3221-5.
19. Grant CE, Valdimarsson G, Hipfner DR et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-61.
20. Müller M, Meijer C, Zaman GJR et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033-7.
21. Cole SPC, Sparks KE, Fraser K et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-10.
22. Cole SPC, Downes HF, Slovak ML. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer 1989; 59: 42-6.
23. Barrand MA, Rhodes T, Center MS. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 1993; 29: 408-15.
24. Vanhoefer U, Cao S, Minderman H et al. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 1996; 2: 369-77.
25. Zaman GJR., Lankelma J, van Tellingen O et al. Role of glutathione in the export of compounds from cells by the multidrug resistance-associated protein. Proc Natl Acad Sci USA 1995; 16: 7690-4.
26. Versantvoort CHM, Broxterman HJ, Bagrij T et al. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing the multidrug resistance-associated protein. Br J Cancer 1995; 72: 82-9.
27. Vanhoefer U, Cao S, Minderman H et al. D,L-buthionine-(S,R) sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res 1996; 2: 1961-8.
28. Vanhoefer U, Yin M-B, Harstrick A et al. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 1997; 53: 801-9.
29. Twentyman PR, Wright KA, Bleehen NM. Modification by SDZ PSC-833 of sensitivity to etoposide, cisplatin, and taxol in multidrug resistant (MDR) cells with glycoprotein (Pgp)-mediated and MRP-associated phenotypes. Ann Oncol 1994; 5 (Suppl 5): 326.
30. Kohn EC, Sarosy G, Bicher A et al. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
31. Piccart MJ, Gore M, Huinink WTB et al. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81.
32. Kaye SB, Piccart M, Aapro M et al. Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials. Eur J Cancer 1995; 31A: 7-14.
33. Sledge Jr. GW, Neuberg D, Ingle J et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc Am Soc Clin Oncol 1997; 16: 1.
34. Bishop JF, Dewar J, Tattersall MHN. Taxol® (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 1997; 16: 153.
35. Chan S, Friedrichs K, Noel D et al. A randomized phase III study of Taxotere® (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: Preliminary results. Proc Am Soc Clin Oncol 1997; 16: 154.
36. Fosella FV, Lee JS, Berille J et al. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22: 22-9.
37. Edelmann MJ, Gandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1996; 37: 385-93.
38. Valero V, Burris III HA, Jones SE et al. Multicenter pilot study of taxotere in taxol-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1996; 15: 107.
39. Toth K, Vaughan MM, Schwartz G et al. MRP and MDR1 expression in 160 human untreated carcinomas studied by immunohistochemical methods in formalin-paraffin sections. Proc Am Soc Clin Oncol 1997; 16: 542.
40. Filipits M, Suchomel RW, Dekan G et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 1996; 2: 1231-7.
41. Chuman Y, Sumizawa T, Takebayashi Y et al. Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 1996; 66: 274-9.
42. Nooter K, Bosman FT, Burger H et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 1996; 7: 75-81.
43. Slovak ML, Ho J P, Cole SPS et al. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: Evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 1995; 55: 4214-9.
44. Slovak ML, Hoeltge GA, Dalton WS et al. Pharmacological and biochemical evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 1988; 48: 2793-7.
45. Skehan P, Storeng R, Scudiero, D et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
46. Shudo N, Mizoguchi T, Kiyosue T et al. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res 1990; 50: 3055-61.
47. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
48. Nicoletti MI, Lucchini V, D'Incalci M, Giavazzi R. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 1994; 30A: 691-6.
49. Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC-833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 1993; 85: 478-83.
50. Mickisch GH, Aksentijevich I, Schoenlein PV et al. Transplantation of bone marrow cells from transgenic mice expressing the human mdrl gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992; 79: 1087-93.
51. Lehnert M, Emerson S, Dalton WS et al. Reversal of P-glycoprotein-associated resistance to taxol and taxotere. Proceedings of Second Natl Cancer Inst Workshop on Taxol and Taxus, Alexandria, VA 1992.
52. Tolcher AW, Cowan KH, Solomon D et al. Phase I cross-over study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1173-84.
53. Chuman Y, Chen ZS, Sumizawa T et al. Reversal of MRP-associated drug resistance by the pyridine analogue, PAK-104P. Proc Am Assoc Cancer Res 1997; 38: 594.
54. Minderman H, Vanhoefer U, Toth K et al. DiOC2(3) is not substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 1996; 25: 14-20.
55. Nooter K, Brutel de la Riviere G, Look MP et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997; 76: 486-93.
56. van der Valk P, van Kalken CK, Ketelars H et al. Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1990; 1: 56-64.
57. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A meta-analysis of MDR1/Pgp170 expression and its possible significance. J Natl Cancer Inst 1997; 89: 917-31.